The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
A federal judge in California has blocked President Donald Trump from building sections of his long-sought border wall with money secured under his declaration of a national...Politicsread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
The race is underway to find a vaccine that can control African swine fever, a highly contagious and deadly viral infection ravaging China's hog population. There is currently...Agricultureread more
Apple bought Tueo Health, which was developing tech to help parents monitor asthma symptoms in children, using a mobile app and commercial breathing sensors.Technologyread more
* Drugmaker posts surprise Q1 rev miss
* Reaffirms its 2019 forecasts
* N.America revenue falls 6 pct (Adds analyst comments, updates shares)
May 7 (Reuters) - Drugmaker Mylan NV on Tuesday reported lower-than-expected quarterly revenue and failed to provide greater clarity on a potential revamp of the company's strategy, sending its shares down 17 percent to a more than six-and-a-half year low.
The company in August announced that its board had launched a strategic review, citing tough pricing environment for generics and said last quarter that the review was nearing completion.
But on a conference call with analysts on Tuesday Chief Executive Officer Heather Bresch declined to say when Mylan would announce its review results, saying it would be in the "near-term."
SVB Leerink analyst Ami Fadia said the delay raises questions about what the board may be considering as part of the review. "Visibility into any strategic changes could be critical in how investors view the stock."
Mylan has been grappling with lower drug prices as well as problems at its Morgantown facility in West Virginia after the U.S. health agency issued a warning letter last year.
Mylan, which also reaffirmed its 2019 forecasts, said its quarterly revenue was hit by lower volumes and a stronger dollar.
"We believe investors had braced themselves for a bottom line miss, but not the revenue weakness," Mizuho Securities analyst Irina Koffler said in a note titled 'bottom line beat irrelevant'.
Drugmakers such as Mylan and Teva Pharmaceutical Industries Ltd have suffered over the past few years as a steep fall in generic prices ate into their profits, but they have lately seen prices stabilizing.
Mylan said it does not expect price erosion in the generics market in the United States to accelerate in 2019.
Revenue from its North America business, its biggest, fell 6 percent to $922.9 million and missed estimates of $952.43 million, while sales at its Europe business dropped 14 percent to $895.3 million, below $1.06 billion that analysts expected.
Total revenue fell 7 percent to $2.50 billion and missed estimates of $2.69 billion, according to IBES data from Refinitiv.
The company reported a net loss of $25 million, or 5 cents per share, in the first quarter ended March 31, compared with profit of $87.1 million, or 17 cents per share, a year earlier.
Excluding items, the company earned 82 cents per share and beat expectations of 79 cents per share.
Shares of the company fell to $23.84 in afternoon trade on Tuesday. Since Bresch took the helm in 2012, Mylan shares have risen nearly 8 percent. (Reporting by Saumya Sibi Joseph, Aakash Jagadeesh Babu in Bengaluru and Michael Erman in New York; Editing by Arun Koyyur)